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Lifestyle counselling as secondary
prevention in patients with minor stroke
and transient ischemic attack: study
protocol for a randomized controlled pilot
study
Jacob Liljehult1,2,3* , Stig Molsted4, Tom Møller2,5, Dorthe Overgaard3, Lis Adamsen2,5, Mary Jarden5,6 and
Thomas Christensen1,6
Abstract
Background: Most patients with minor stroke or transient ischemic attack (TIA) are discharged with little or no
specialised follow-up. Nonetheless, these patients have a high prevalence of cognitive impairments and a
considerable risk of recurrent stroke. Smoking cessation, physical activity, and adherence to antihypertensive and
antithrombotic medication are highly recommended in patients with minor stroke and TIA. Evidence suggests that
simple encouragement to change lifestyle is ineffective. Behavioural interventions might therefore be needed to
support patients in managing their own health post-discharge.
Objectives: We aim to test the (1) feasibility of randomisation acceptance and an early initiated, client-centred
lifestyle and behavioural intervention in a clinical setting, and (2) potential effect of the intervention on arterial
blood pressure in patients with minor stroke or TIA and (3) explore the participants experience of barriers and
facilitators for health behaviour after a stroke, including perceived needs and social support.
Methods: We will conduct a randomized controlled pilot trial: Eligible patients with acute minor stroke or TIA (n =
40) will be randomly allocated to either early initiated counselling with four weekly post-discharge follow-up
sessions for 12 weeks or usual care. The primary outcome will be program feasibility and to discuss the relevance of
arterial blood pressure as primary outcome after 12 weeks intervention. Selected participants will be invited to
participate in semi-structured interviews, based on purposeful sampling, to evaluate the intervention and explore
their experience of life after a stroke. The interviews will be analysed using a five-step thematic analysis approach.
(Continued on next page)
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Discussion: The study will provide evidence of the feasibility and potential effect of early initiated counselling on
cardiovascular risk factors in patients with minor stroke and TIA. Qualitative interviews will contribute with a more
nuanced understanding of the barriers and facilitators of health enhancing behaviour. Optimizing health behaviour
counselling and providing formal support to the patients’ post-discharge may ease the transition and help more
patients adhere to lifestyle and medication recommendations.
Trial registration: ClinicalTrial.gov, NCT03648957
Keywords: Stroke, Transient ischemic attack, Smoking, Exercise, Physical activity, Adherence, Early rehabilitation,
Health counselling
Background
Stroke is a significant cause of morbidity, mortality, and
disability in both western countries and globally [1]. In
Denmark, the incidence rate is 3/1000 per year, with a
mortality rate of 10% in the first month [2]. More than
half of patients admitted with a stroke or transient ische-
mic attack (TIA) only have mild neurological symptoms
and are often discharged after 3-5 days of hospital ad-
mission. In spite of this, there is evidence that the pa-
tients after discharge often experience cognitive and
communicative impairments such as difficulties with
everyday activities, memory, fatigue, reading and partici-
pating in conversations [3]. This indicates that patients
with recent minor stroke or TIA need more support
than previously assumed.
One in four patients admitted with acute stroke has pre-
viously suffered a stroke or TIA. The risk is greatest
shortly after the incident stroke; and within the first year
the recurrence rate is 12-13% and subsequently plateauing
at 5-6% per year [4]. Recurrent stroke is an independent
risk factor for loss of function, institutionalization and
death [5].
In the past decades, there has been an increasing focus
on health behaviour in relation to the prevention of
vascular diseases [6]. Arterial hypertension is the most
important and prevalent risk factor for stroke and TIA
(odds ratio (OR) 2.64 [2.26-3.08]; Population Attribut-
able Risk (PAR) 34.6%). However, other lifestyle factors,
such as smoking (OR 2.09 [1.75-2.51]; PAR 18.9%), physical
inactivity (OR 1.45 [1.11-1.89]; PAR 28.5%), abdominal
obesity (OR 1.42 [1.18-1.71]; PAR 26.5%), and unhealthy
eating habits (OR 1.35 [1.12-1.61]; PAR 18.8%) contribute
to the risk of stroke [7].
Preventive medication is of utmost importance for sec-
ondary and tertiary prevention in patients with stroke
and TIA. The majority of patients are treated with anti-
thrombotic drugs or drugs to reduce blood pressure or
blood lipids [8]. However, several studies have found
that a substantial part of the patients discontinue the
drug treatment overtime [9, 10].
The harmful effects derived from lifestyle factors, and
the importance of adherence to preventive medication in
relation to stroke is well-documented [10, 11]. But there
is still insufficient knowledge regarding how to most ef-
fectively communicate this to the patients and how to
support the patient in making suitable choices to pre-
vent recurrent strokes and progression of the disease.
The results from previous studies have been contradictory.
It is difficult to identify the most effective components
and recommend specific interventions or components of
interventions for implementation in clinical practice.
Lawrence et al. [12] found in a systematic review of 20
randomized controlled trials that multimodal behavioural
interventions had a beneficial effect on blood pressure in
patients with stroke. Deijle et al. [13] found that lifestyle
interventions had a greater effect if the intervention con-
tained elements of physical activity. Lager et al. [14] on
the contrary found no significant reduction in cardiovas-
cular events in a systematic review of 26 randomized con-
trolled trials of lifestyle intervention for stroke patients.
The time of inclusion in previous stroke/lifestyle inter-
vention studies varied from a few days after stroke onset
[15, 16] to several years [17]. The timing of the interven-
tion might affect the patient’s motivation and ability to
adhere to the intervention, which will ultimately have an
effect on the outcome. In other patient groups, it has
been hypothesised that the time just after the diagnosis
constitutes a certain window of opportunity; i.e. a limited
period of time in which the patient is particularly recep-
tive to information and behavioural changes [18].
The hypothesis of the present study is that early
client-centred patient counselling with repeated follow-
up sessions after discharge can reduce the blood pres-
sure through smoking cessation, physical activity, and
improved adherence to preventive medication in patients
with minor stroke or TIA compared to simple encour-
agement to lifestyle change. The overall purpose of our
research is to develop effective and clinically feasible in-
terventions to support patients with minor stroke and
TIA in engaging in health enhancing behaviour and ul-
timately prevent recurrent strokes.
Little research has explored how old age and cognitive
impairments of this patient group affects their ability,
readiness and willingness to participate in early initiated
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health behavioural interventions or if there are particular
circumstances both during admission and post-discharge
that should be taken into account when designing this
type of research study.
The aims of this study are the following:
1) to evaluate the feasibility of a client-centred patient
counselling intervention focused on smoking
cessation, physical activity, and adherence to
preventive medication in patients with minor stroke
or TIA
2) to test the potential effects of the intervention on
blood pressure and other cardiovascular risk factors
in patients with minor stroke or TIA, and estimate
means and standard deviations for subsequent
sample-size calculations
3) to explore and evaluate the perceived needs and
experience of social support of the participants in
relation to health behavioural changes
Methods
The study will consist of a parallel group randomized
controlled feasibility trial and a qualitative interview
study. Participants will be randomly allocated to either
an individual face-to-face counselling intervention, with
follow-up sessions post-discharge at 4 week intervals for
12 weeks, or usual care. Semi-structured qualitative in-
terviews will be conducted with selected participants
after the last follow-up.
Setting and participants
The target population is hospitalised patients with recent
minor stroke or TIA who are discharged home from the
hospital.
We will include patients with acute minor stroke or TIA
admitted to the Department of Neurology at Nordsjællands
Hospital (n = 40). Nordsjællands Hospital is a university
hospital with a catchment area of 310,000 citizens. All pa-
tients with stroke or TIA in the catchment area are admit-
ted to the hospital and treatment is free of charge. The
Department of Neurology has a specialized unit for patients
with acute stroke and treatment is guided by a standardized
patient pathway. Patients with minor stroke and TIA are
generally hospitalised for observation for 72 h.
Study and recruitment procedures
All new patients at the Department of Neurology will be
screened for eligibility by the research investigator (JL).
Patients are eligible if they are ≥ 18 years old, are diag-
nosed with TIA (ICD-10 G45.9) or minor stroke (ICD-
10 I61, I63, I64; Scandinavian Stroke Scale 45-58), are
discharged to their home, and can provide valid written
consent. Diagnoses must be confirmed by a neurologist.
Patients are excluded from the study if they have severe
communication barriers, are not able to use a telephone,
have severe disability prior to the stroke (WHO Per-
formance Status > 2; incapable of self-care and mobilised
less than 50% of the day), have an active abuse of alcohol
or narcotics or have a severe psychiatric illness (affective
disease, dementia, schizophrenia, anxiety). Eligible pa-
tients will be invited to participate through verbal and
written information regarding the study purpose and
method by JL. All participants must give written in-
formed consent before participation. Participant flow is
summarised in Fig. 1.
Randomization and group allocation
Simple non-stratified 1:1 randomisation will be used to
allocate participants into two trial arms (intervention or
usual care) after baseline testing. Randomization will be
conducted in the Research Electronic Data Capture
(RedCap) software [19] using a computer generated
randomization sequence. The randomization sequence
will be generated by JL, then concealed in RedCap, and
any changes can only be made by an external adminis-
trator. Participants will be automatically randomized
after baseline testing and the allocation will be subse-
quently locked and cannot be altered. Participants will
remain in the allocated arm for the entire intervention
period.
Intervention
Participants in the intervention arm will receive usual
care and a nurse-led targeted lifestyle counselling focus-
ing on smoking cessation, everyday physical activity, and
adherence to preventive medication. The initial counsel-
ling will be provided face-to-face by a research investiga-
tor before the participant is discharged from the
hospital. The aim of the counselling will be to engage
the participant to partake a healthy lifestyle and adhere
to the preventive medication and to assist the participant
in finding suitable strategies to achieve his/her goals.
Participants will be encouraged to bring a relative or
close friend to the initial counselling session, who can be
a support for the participant after discharge. The coun-
selling will be based on the 5A’s approach (Ask/assess,
Advice, Agree, Assist and Arrange, see Fig. 2) [20, 21].
Ask/assess. At baseline all participants will be asked
about self-rated health, smoking habits, and physical ac-
tivity, and body mass index, waist/hip-ratio and lung
capacity will be assessed. During the counselling, the
participants are asked to reflect on the following: the
relevance of changing behaviour; how the specific behav-
iour affects their risk of disease; how they think changing
behaviour could be beneficial as well as perceived bar-
riers and facilitators of behavioural change. Perceived
barriers and facilitators for changing behaviour can be
both personal (e.g. attitudes towards changing behaviour,
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attribution of risk and self-efficacy) and environmental
(e.g. products, technology, surroundings, social support
and services). The focus at this point in the counselling
is not to find solutions, but to facilitate the participant’s
reflection on his or her health and health behaviour. Ad-
vise. The participant is given clear, specific and personal
recommendations, including information on potential
harms and benefits to their health and well-being. Agree.
The participant is supported in setting goals. Assist. The
investigator assists the participant in finding strategies to
achieve the agreed-upon goals and helps the participant
in acquiring the skills, confidence and social support
within the participant’s own environment to change be-
haviour. The strategies should be grounded in the previ-
ous reflections and customised to the needs, capacities,
and preferences of the individual participant. Arrange.
Follow-up sessions are arranged and, if necessary, the
participant is referred to other relevant treatments.
Prior to of the initial counselling session a de-
tailed assessment of the participant’s lifestyle and
physical condition will be conducted by JL (research
investigator); including spirometry (FEV1/FVC mea-
sured using SpiroBank II) [22] and aerobic capacity
(Åstrand-Rhyming Bike Test) [23].
Further counselling will be provided by telephone 4 and
8 weeks after discharge and will aim at maintaining motiv-
ation and adjusting goals and strategies if necessary. If the
participant has not previously been motivated for chan-
ging behaviour, the willingness for change is re-assessed.
All parts of the intervention will be delivered by JL,
who has extensive clinical experience as a nurse in the
field of neurology.
After each counselling session, a written summary is
included in the electronic patient record which is avail-
able to the participant via a personal log-in. The partici-
pant’s relatives will be involved in the counselling at the
participant’s discretion to facilitate social support. Social
support might be of particular importance in partici-
pants with cognitive impairments or limited ability to
take in information.
The level of physical activity in the intervention arm
will be monitored throughout the intervention period
using an electronic activity tracker (Garmin VivoFit 4),
which measures steps, intensity (light/moderate/vigorous
activity) and estimated calories burned. The activity
tracker should work as a reminder and motivator for
everyday physical activity but will also provide feedback
to support the post-discharge counselling.
Fig. 1 Flowchart of recruitment, inclusion, allocation and follow-up of participants
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Usual care
Participants in the control arm will receive standard
care, which includes a review of prescribed medication,
and both verbal and written encouragement of a healthy
lifestyle (see Table 1) [24].
Participants from both treatment arms will be re-
assessed in the hospital-based outpatient clinic 12 weeks
after they are discharged from the hospital. The evalu-
ation will include arterial blood pressure, smoking status,
body mass index, waist/hip-ratio, and adherence to pre-
ventive medication (proportion of missed doses in the
past 7 days) Fig 2.
Study tests and assessments
Baseline and outcome measures are summarised in
Table 2.
Baseline data
After written consent has been obtained baseline data will
be collected by the research investigator. Demographic
Fig. 2 The 5A’s approach adapted from Vallis et al 2013 and Sherson et al 2014
Table 1 Standard recommendations for a healthy lifestyle after
stroke or TIA in Denmark [24]
• Smoking cessation is encouraged
• Regular physical activity is encouraged to the extent of the patient’s
ability
• Patients with a substantial use of alcohol (> 7/14 units of alcohol per
week for women and men, respectively) should reduce the
consumption of alcohol or cease to use alcohol all together
• Patients are encouraged to eat a diet high in fruits, vegetables,
wholegrain products, and sea food; and to limit the intake of salt and
saturated fats
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data will include age, gender, living arrangements, educa-
tional level and ECOG performance status [25] prior to
stroke onset. Lifestyle factors will include self-rated health,
smoking habits, alcohol consumption and anthropometric
measures, assessed using standardised questions from the
Danish National Health Survey Questionnaire [31]. The
International Physical Activity Questionnaires short form
(IPAQ-SF) [32] will be used to assess the level of physical
Table 2 Baseline and outcome parameters
Parameters Methods Baseline test Discharge 12-weeks follow-up 1-year follow-up
Baseline data
Demographic data X
Age, gender, living conditions, education, performance
status [25] prior to stroke
Health status
Stroke type ICD-10 I61, I63, I64, G45.9 X X
Stroke severity Scandinavian Stroke Scale [26] X
Vital signs Early warning score [27] X
Heart arrhythmia Result of 48-72 h telemetry [28] X
Prior health problems Charlson comorbidity index [29] X
Biochemistry Glucose, HbA1c, cholesterol, LDL,
VLDL, HDL, triglycerides [11]
X
Prescribed medication Prescribed preventive medication
(Antihypertensives, antithrombotic,
anticoagulatives, NOAC, statins)
X
Primary outcome
Eligibility rate X
Study participation rate X
Adherence to the program X
Attrition rate X
Satisfaction X
Secondary outcome X
Resting arterial blood pressure Average of two or more measurements
in sitting position after > 10 min resting
according to 2017 US Guidelines [30]
X X
Tertiary outcomes
Current smoking Self-reported tobacco smoking (daily,
weekly, rarely, has quit smoking, never
smoked) [31]
X X
Physical activity Self-reported participation in leisure time
physical activities (minutes per week of
light/moderate/strenuous) [32]
X X
Body composition Body mass index, hip/waist ratio X X
Fatigue Fatigue Assessment Scale [33]; 10-item
questionnaire
X X
Self-rated health Self-rated health current and in the last
year [31]
X X
Adherence to preventive medication Adherence to preventive medication
(Antihypertensives, antithrombotic,
anticoagulatives, NOAC, statins) the last
7 days prior to assessment
X
Units of alcohol per week Self-reported [31] X X
Recurrent stroke/TIA Patient medical report data X
Ischemic heart disease Patient medical report data X
All-cause mortality Danish Central Person Registry X
LDL low-density lipoprotein, VLDL very low-density lipoprotein, HDL high-density lipoprotein, NOAC novel oral anticoagulants
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activity prior to admission. Scandinavian Stroke Scale [26]
will be used to assess stroke severity. Charlson Comorbidity
Index [29] will be used to assess the burden of comorbidi-
ties. Early Warning Score [27] will be used to summarize
vital signs. Serum lipids (total cholesterol, HDL, LDL,
VLDL, triglycerides), random blood glucose and HbA1c are
routinely collected on all patients [11].
Outcome measures
Measures of feasibility
The primary outcome measures are the following:
1) the eligibility rate (proportion of eligible patients
compared to the total number of stroke patients)
2) the study participation rate (proportion of patients
accepting participation in the study)
3) the degree of adherence to the program (proportion
of attendance in follow-up sessions)
4) attrition (drop-out and withdrawal)
5) participant satisfaction with the intervention,
using both quantitative (Likert scale) and
qualitative (semi-structured interviews) measures,
to guide the design of a future full-scaled
randomized controlled trial
Measure of potential effect
The secondary outcome measure will be arterial blood
pressure measured before and 12 weeks after the start of
the intervention. Measurements will be performed in ac-
cordance with the American Heart Association guide-
lines [30]. To avoid extreme values, the blood pressure
will be measured at least twice. If the two measurements
of the systolic pressure are more than 5 mmHg apart the
measurement will be repeated. The average of the last
two measurements will be used for analysis.
Other outcome measures
Tertiary outcomes after 12 weeks will include the fol-
lowing: self-reported smoking status, physical activity
level (IPAQ-SF) [32], adherence to medication (num-
ber of missed/consumed doses in the past seven days),
anthropometrics (body weight, waist/hip ratio) and Fa-
tigue Assessment Scale [33].
Long term outcome
All participants will be followed up twelve months after
the incident stroke/TIA through the national patient
registry, which contains information on all patient ad-
missions in Danish hospitals. The outcome measure will
be recurrent strokes/TIA, myocardial infarcts, other car-
diac admissions and death.
Analysis plan
Quantitative data
Data will be entered into a RedCap database in real-time
using electronic case report forms. Statistical analyses
will be carried out using R 3.3.1/R Studio 0.99.
Recruitment, randomization, allocation and follow-up
will be reported in a flow-chart stating the number of
participants at each step. Characteristics of participants
and non-participants (e.g. excluded, non-consenting or
lost to follow-up) will be reported as detailed as pos-
sible according to CONSORT guidelines for feasibility
studies [34].
Baseline data on participant demographics and charac-
teristics will be presented in a descriptive table in ac-
cordance with the CONSORT guidelines.
The primary endpoint (12 weeks study retention in the
two randomization groups) will be reported as absolute
numbers and proportions with 95% confidence intervals.
The secondary endpoint (arterial blood pressure) will be
reported as an absolute number for each group and esti-
mate of the between group difference with 95% confi-
dence intervals. Twelve months follow-up data will be
reported as absolute numbers, absolute risk reduction
and risk ratio (with 95% confidence intervals) comparing
the risks of a negative event (recurrent stoke, TIA, car-
diovascular incident or death) in the two groups. An
intention-to-treat approach will be employed in the ana-
lysis of all endpoints.
Qualitative data
Based on purposeful sampling [35] selected participants
from both randomization groups will be invited to par-
ticipate in in-depth semi-structured interviews. The
participants are encouraged to invite a relative to partici-
pate in the interview. The sampling strategy will aim at
achieving maximal variation concerning sex, time since
discharge, and whether they have been successful in
changing behaviour. The sample size will be based on
achieving theoretical data saturation (expected n = 15 −
20). A semi-structured interview guide will be designed
to give structure to the interviews.
The interviews will be digitally recorded and tran-
scribed, and analysed using thematic analysis as described
by Braun and Clarke [36]. The qualitative software system
NVivo version 12 (QSR International) will be used to
organize data and support the process of analysis.
Approvals and registrations
The study protocol has been approved by the Scientific
Committee of the Capital Region (H-17040484) and the
Danish Data Protection Agency (j.nr. VD-2018-306, I-
6552). The study protocol is registered at ClinicalTrials.
gov (NCT03648957).
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Discussion
Most patients with TIA and minor stroke are discharged
to their own home with little or no specialised follow-
up. Previous studies have reported a high prevalence of
cognitive impairments such as poor memory, fatigue and
difficulty with reading and writing [3] as well as a high
risk of stroke recurrence [37, 38]. The overall purpose of
the current study is to develop an early initiated, client-
centred behavioural intervention to support patients
with minor stroke and TIA in managing their own
health post-discharge. The intervention is pragmatically
integrated within the existing standard treatment and
guidelines.
Self-management of health is complex and requires both
knowledge, skills, and confidence [39]. Optimizing coun-
selling and providing formal support from health profes-
sionals might help patients obtain a greater adherence to
lifestyle recommendations and medication prescriptions.
The rationale behind early initiation of the interven-
tion was an assumption that patients might be more sus-
ceptible to information and behavioural change close to
the initial event. In studies of other patient populations,
it has been hypothesized that the time close to the initial
diagnosis constitutes a certain window of opportunity,
i.e. a limited period of time where the patient is more re-
ceptive to information [18]. In previous studies of behav-
ioural interventions in patients with stroke and TIA, it
has been shown that the time of inclusion has varied
from a few days to several years post-stroke [15–17].
This might be part of the reason why results have been
inconsistent.
Part of the purpose of the pilot study will therefore be
to examine whether the patients are willing and able to
participate in this type of intervention in the early phase
of their disease. We anticipate that some patients will
not be ready to participate at this stage, either because
they find it too overwhelming to participate or because
they are unable to take in the amount of information
needed to engage in behavioural change.
Furthermore, we will examine whether it is feasible to
initiate and complete the counselling within the limited
time of admission in an acute setting. Patients with
minor stroke and TIA are generally hospitalized for 3-4
days (72 h of observation) and this time frame might
prove to be difficult to identify and include relevant pa-
tients in the study and provide the intervention.
Smoking, physical activity, and adherence to prevent-
ive medication were chosen as the main focus of the
counselling intervention as these factors have been
shown to be both modifiable [40, 41] and, in our judge-
ment, were the most likely to have an impact on the sys-
tolic blood pressure [42, 43].
Systolic blood pressure was chosen as the main meas-
ure of effect because it is the greatest risk factor of both
ischemic and haemorrhagic stroke [7] and has been
demonstrated to be modifiable in previous intervention
studies [12].
The randomized controlled design will be used to test
the feasibility and acceptability of the overall study
methodology and the specific elements of the interven-
tion. This includes testing whether the screening proced-
ure is suitable for identifying relevant patients, inclusion
and exclusion criteria has the right balance of sensitivity
and specificity, the procedure of recruiting and attaining
consent is suitable, and delivery of the intervention and
follow-up is acceptable. Through this process, we will
gain knowledge and experience which can guide further
development of the study protocol [44].
The qualitative interviews with the study participants
will be used to gain insights into the lived experience of
life going home after hospitalisation for stroke, as well as
their experience of managing their own health. This will
give us a more profound understanding of the needs of
patients who are discharged from the hospital and which
type of support and counselling should be provided be-
fore and after the discharge.
Furthermore, the qualitative interviews will be used to
evaluate the randomized controlled trial and the inter-
vention. Even though this area of research is relatively
new, previous studies have found that engaging patients
and other stakeholders in the development of clinical
studies might help the researcher in developing more
meaningful and feasible methods and to identify more
useful outcome measures [45]. The qualitative interviews
might also contribute with a deeper and more nuanced
understanding of the barriers and facilitators of health
enhancing behaviour in patients with stroke. The needs
of this particular group of patients might differ from
other patient groups because of the combination of older
age and cognitive impairments.
A key part of a pilot study is to evaluate the feasibility
of conducting a full-sized trial in the future.
A potential impediment for conducting a full-sized trial of
this type might be a restricted number of willing partici-
pants. To assess whether a full-sized trial is feasible, we must
therefore (1) assess how many participants can realistically
be recruited within a reasonable time period, and (2) analyse
available data on non-participants and low adherence to find
potential strategies to reduce non-participation.
Limitations
The present study will have some limitations. First off,
we wish to evaluate the feasibility of the study design
and the intervention, and the sample size of the study
will therefore be limited increasing the risk of both type
1 and type 2 error. The sample size of 40 participants
was not based on a formal sample size calculation, but
rather on a pragmatic estimate of how many participants
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we would be possible to recruit within a reasonable
timeframe, knowing full well that the trial would likely
be under-powered for hypothesis testing. Though we as-
sumed that 40 participants would be enough to reliable
test all procedures of the trial even with a substantial
rate of attrition.
The measurement of blood pressure will be done ac-
cording to a standardized study manual to increase the
validity and reliability. Self-reported data at baseline and
follow-up will be collected using the same method in
both treatment groups to minimize information bias.
Given the nature of the intervention the possibility of
blinding is limited. Blinding of the assessors or participants
is not possible in studies in which patient activation and
counselling is part of the intervention. However, blinding in
the analysis of the quantitative data will be possible.
Ethical considerations
The study will be conducted in accordance with the
Helsinki Declaration [46] including respect for the par-
ticipants’ autonomy and right to informed consent. Par-
ticipants will be informed that participation is voluntary,
and that participation can be declined at any time and
without explanation. Participant data will be kept confi-
dential in accordance with guidelines from the Danish
Data Protection Agency.
The inconveniences of participating will be minor, and
we are convinced that the potential benefits will outweigh
the drawbacks. Withdrawal symptoms associated with
smoking cessation and muscle soreness associated with in-
creased physical activity are to be expected. Generally, these
will be both minor and transient [47, 48]. Participants will
be encouraged to report any suspected adverse effects, in-
cluding side effects to the medication as this might affect
adherence. At all follow-up contacts (telephone and out-
patient), the participants will be asked if they have experi-
enced adverse effects or side effects to the medication. If
potentially serious adverse effects are reported, a depart-
ment physician will be consulted. All reports of adverse or
side effects will be qualitatively evaluated and quantitatively
compared between the trial arms.
The use of a control group as a comparison is necessary
if we wish to find evidence of the potential hypothesized
effect of the treatment and gain a better understanding of
the variation in the outcome measures. It will also be ne-
cessary to test the feasibility of the randomization process
prior to the design of a full scale randomized controlled
trial. The treatment of the participants in the control
group will at no point be inferior to the treatment of non-
participants.
Dissemination
Results of the study will be published in international peer-
reviewed scientific journals and presented at national and
international conferences. Results will be made public re-
gardless of them being positive, negative, or inconclusive.
The principal investigator (JL) will draft all publica-
tions under the supervision of the other members of the
project group. The order of authorship will be in order
of contribution and has been agreed upon in the project
group beforehand. The rights and responsibilities of the
authors will be in accordance with The Danish Code of
Conduct for Research Integrity [49] and the ICMJE rec-
ommendations [50].
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Recruitment has been completed in January 2020.
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